Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESERVE: Cryopreserved HLA-Mismatched Bone Marrow Transplant for Hematologic Malignancies
NCT05170828Phase 1Withdrawn
- Sponsor
- Ossium Health
- Start
- Sep 2022
- Primary completion
- Mar 2024
01
Overview
Phase 1, open-label trial in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and 3 more, sponsored by Ossium Health. Primary endpoints: Neutrophil engraftment at Day 35, Cumulative incidence and kinetics of neutrophil and platelet recovery at Day 35 and 1 more. Planned start Sep 2022; status: withdrawn.
02
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)T-cell lymphoblastic lymphoma (T-LBL)Acute Biphenotypic Leukemia (BAL)
Beyond the preview
Go deeper on NCT05170828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05170828.